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Abstract
Background: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality among women.
Women with CVD experience a greater burden of psychosocial distress than men, and practice guidelines promote
screening in cardiac patients, especially women. The objectives herein were to describe the burden of psychosocial
distress, extent of screening, forms of treatment, and whether receipt of treatment was related to psychosocial
distress symptom severity at follow-up, among women.
Methods: Within a multi-center trial of women randomized to cardiac rehabilitation models, consenting participants
were asked to complete surveys upon consent and 6 months later. Clinical data were extracted from charts. This study
presents a secondary analysis of the surveys, including investigator-generated items assessing screening and treatment,
the Beck Depression Inventory-II, the Hospital Anxiety and Depression Scale, and Patient Health Questionnaire-2.
Results: Of the 128 (67.0%) participants with valid baseline and follow-up survey results, 48 (40.3%) self-reported that
they recalled being screened, and of these, 10 (21.3%) recalled discussing the results with a health care professional.
Fifty-six (43.8%) retained participants had elevated symptoms of psychosocial distress at baseline, of which 25 (44.6%)
were receiving treatment. Regression analyses showed that treatment of psychosocial distress was not significantly
associated with follow-up depressive symptoms, but was significantly associated with greater follow-up anxiety.
Conclusions: Findings reiterate the great burden of psychosocial distress among women with CVD. Less than half of
patients with elevated symptoms were treated, and the treatment approaches appeared to insufficiently achieve
symptom relief.
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Background
Globally, cardiovascular disease (CVD) is the leading
cause of morbidity and mortality in women and men,
representing 30% of all deaths worldwide [1]. Depression
and anxiety are two of the most frequent co-morbidities
associated with CVD, increasing the overall impact of
disease. Approximately 30% of patients who have been
hospitalized for a myocardial infarction experience
depressive symptoms, of which 15–20% suffer from major
depression [2]. The prevalence of anxiety has been less-
studied, but there is an understandable elevation of symp-
toms of anxiety following an acute CVD event [3].
Both symptoms of depression and anxiety post-
myocardial infarction are associated with an increased risk
of experiencing recurrent cardiac events [4]. Co-morbid
depression is associated with a two-time greater risk of
mortality in patients with CVD [5], and is inversely related
to the adoption of secondary prevention behaviors, includ-
ing smoking cessation and participation in cardiac re-
habilitation (CR) [2].
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The prevalence of major depression in women with
CVD is twice that of men. Women also tend to experi-
ence greater anxiety after a cardiac event [6].
Cardiovascular clinical practice guidelines recommend
routine screening for depression following a cardiac event
[7–10]. The American Heart Association recommends
screening with the Patient Health Questionnaire (PHQ)-2
[7]. The limited evidence available shows few cardiac
patients are screened in the inpatient setting. A recent
review identified that there has been no evaluation of
whether screening in the outpatient cardiology setting is
useful [11]. In addition, it has not been investigated how
and whether patients are being fully informed they are
being screened for depression.
Evidence-based therapies for depression and anxiety are
well-established [12, 13], and have been tested in the CVD
population [14–17]. There is some emerging evidence that
treatment, including psychotherapy, pharmacology, and a
combination of the two, not only reduce psychosocial dis-
tress (i.e. symptoms of depression and anxiety) [14–18],
but also can reduce the risk of recurrent CVD events [19]
and improve overall prognosis [14, 20]. Exercise as part of
CR has also been shown to reduce depressive symptoms,
as well as morbidity and mortality [19].
There are some reports of unsuccessful treatment of co-
morbid depression among women, and in fact that psycho-
social treatment may be associated with adverse outcomes.
The results of the Montreal Heart Attack Readjustment
Trial [21] demonstrated that women in the treatment arm
displayed slightly higher cardiac and all-cause mortality
compared to usual care and minimal improvements in
depressive and anxious symptom severity were reported.
Furthermore, although not significant, results showed that
outcomes for women in the Enhancing Recovery in
Coronary Heart Disease Patients trial appeared better
under usual care, compared to men in whom outcomes
were more favorable with treatment [15]. Results of these
studies suggest that a better understanding is needed of ef-
fective psychological therapies for women with CVD [15, 21].
The objectives of this study were to: (1) describe rates of
psychosocial distress screening recall, as well as outcome of
such screening. In addition, (2) describe the number of
women considered to be experiencing elevated symptoms
of depression and/or anxiety. In women with elevated
symptoms of psychosocial distress, the aims were to: (2a)
describe the proportion treated, (2b) the types of treatments
received, and (2c) the type of provider from whom they re-
ceived treatment. In the case of pharmacological treatment,
the aims were to: (2d) describe the class of medications
prescribed, (2e) patient adherence, and (2f) if the medica-
tion had been changed or titrated between baseline and
follow-up testing. Finally, the last objective was to: (3) describe
whether receipt of treatment was related to depressive/
anxious symptom severity at follow-up.
Methods
Design and procedure
This study presents a secondary analysis of a single-blind
pragmatic randomized controlled trial of female outpa-
tients with CVD randomized to one of three types of CR,
to understand the effects of program model on adherence
[22]. The design herein for this sub-study is observational
and prospective. The study was approved by the Research
Ethics Boards of the participating hospitals, as well as
York University’s Office of Research Ethics (2009-323).
Participants were recruited from six inpatient and out-
patient cardiac units in the Greater Toronto Area of
Ontario, Canada. Written consent was obtained from all
eligible and willing participants. Participants were then ran-
domized to one of three CR program models: (1) mixed-
sex traditional CR, (2) women-only hospital-based CR, and
(3) home-based CR. Participants in the women-only model
who were not participating in the larger trial were also
approached to participate in an observational sub-study,
where the same assessments were administered.
CR was delivered in 3 centres; 1 centre had a part-time
psychologist and social worker and the others had estab-
lished relationships with mental healthcare providers to
whom they could refer patients external to their program.
Each program and model were delivered in accordance
with the Canadian CR clinical practice guidelines [10],
including an initial assessment of risk factors including
depression symptoms. The 3 centers routinely administer a
paper-and-pencil depression survey. Given this consistency,
model attended would not have an impact on the objectives
herein (for example differences in screening by program
model were tested and no difference was observed; p = .60).
CR programs were 4–6 months in duration.
Clinical information was extracted from inpatient and/
or outpatient medical charts. Prior to CR initiation, partic-
ipants were asked to complete a self-report survey, which
included a number of standardized and validated scales
assessing psychosocial distress, medication adherence,
medication use, exercise behavior and socio-demographic
characteristics.
Follow-up assessments occurred 6 months later by mail.
The self-report survey again assessed psychosocial dis-
tress, medication adherence, medication use, and exercise
behavior. Moreover, an audit of CR charts was undertaken
to ascertain CR enrollment and completion. Response rate
was optimized through repeated and personalized con-
tacts [23]. This included a replacement survey mailing and
telephone calls, if required.
Participants
Participants in this study were consenting women inpa-
tients or outpatients with documented coronary artery dis-
ease, and/or acute coronary syndrome, and/or undergoing
revascularization (percutaneous coronary intervention or
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coronary artery bypass grafting), and/or valve surgery.
These chosen cardiac indications were based on accepted
standard CR referral recommendations [9, 10].
Inclusion criteria were: patient resided in Toronto or
Hamilton, within 45 min of CR site; proficiency in the
English language, and eligibility for home-based CR. Ex-
clusion criteria were: (1) musculoskeletal, neuromuscu-
lar, visual, cognitive or non-dysphoric serious psychiatric
condition (e.g., schizophrenia), or any serious or ter-
minal illness not otherwise specified which would pre-
clude CR eligibility based on CR guidelines [10], (2)
physician deemed patient not suitable for CR at time of
intake exercise stress test, (3) patient planned to leave
the region prior to the anticipated end of participation,
(4) patient discharged to a long-term care facility, and
(5) participation in another clinical trial with behavioral
interventions.
Measures
Socio-demographic characteristics were assessed in the
initial participant survey through forced-choice response
options, including: age, ethnic background, marital sta-
tus, education, income, work status and dependents.
Clinical data extracted from medical charts included car-
diac diagnoses, risk factors, and co-morbid conditions.
Exercise behavior was also measured in the final survey,
considering its relation to mood [24, 25] using the Godin
Leisure-time Exercise Questionnaire [26]. This is a brief
and reliable instrument that was used to assess usual
leisure-time physical activity behavior during a 1-week
period. Lastly, CR participation (also involving exercise)
was verified via an audit of participants CR charts.
Assessment of psychosocial distress: depressive and
anxious symptoms
Psychometrically-validated scales were administered in
both the baseline and follow-up self-report surveys to as-
sess psychosocial distress. First, the Beck Depression
Inventory-II (BDI-II) [27] was administered to assess
depressive symptoms in the baseline survey. It is a reliable
and well-validated 21-item scale that uses a 4-choice
response format. It has been widely used in the general
population and in populations with long-term illness, in-
cluding cardiac disease. This scale has high internal
consistency and good sensitivity for detection of depres-
sion in cardiac patients [28]. Higher scores reflect greater
depressive symptomatology, with scores ≥14 reflecting
“elevated” (i.e., mild to severe) symptomatology.
Second, the Patient Health Questionnaire-2 (PHQ-2)
[29] was administered in both the baseline and follow-
up surveys to assess the frequency of the two cardinal
features of depression, namely depressed mood and an-
hedonia. The PHQ-2 total score ranges from 0 to 6, with
a score of ≥3 indicating elevated symptoms [29]. This
scale has been widely used in the cardiac population.
Finally, The Hospital Anxiety Depression Scale (HADS)
[30] was administered in the follow-up survey, to add-
itionally assess anxiety. The HADS is a 14-item question-
naire with seven items assessing anxiety and seven items
assessing depressive symptoms (primary outcome). Each
item is scored from 0 to 3, with each subscale scored out
of 21. Scores of ≥9 represent elevated symptoms of anxiety
or depression [30, 31]. This scale has been tested in the
cardiac population, and has high internal consistency and
good sensitivity [28].
Assessment of psychosocial distress: screening recall and
treatment
Investigator-generated items assessing problems with, and
treatment for depression and anxiety were incorporated in
both surveys. In the initial survey, participants were asked if
they had current problems with depression and/or anxiety
(yes/no). In both initial and final surveys, participants were
also asked if they were receiving treatment (yes/no), the
type of provider from whom they were receiving treatment,
and finally the type of treatment they were receiving (i.e.,
pharmacotherapy, psychotherapy, or both). In the final sur-
vey, participants were asked whether they had been
screened for depression and/or anxiety since they were re-
ferred to CR (yes/no), and the outcome of such screening.
Use of psychoactive medication was ascertained by
reviewing self-reported medication lists. Participants
were asked in both initial and final surveys to record all
medications they were currently taking, and the dose per
day. Psychoactive drugs were coded according to their
drug class [32]. Whether the psychoactive medication(s)
listed were different on the baseline and follow-up sur-
vey was also assessed, and where the same medication
was reported at both assessment points, whether the
dosage had been changed.
Finally, adherence to medication was assessed via
Morisky’s Medication Adherence Scale (MMAS-4) [33],
which was administered in both baseline and follow-up
surveys. It is a brief and reliable instrument used to
assess medication adherence. The MMAS-4 total score
ranges from 0 to 4, with any score less than 2 indicating
non-adherence.
Analysis
All statistical analyses were performed using SPSS version
20 [34]. Comparisons of socio-demographic, clinical and
psychosocial characteristics between participants retained
and those lost-to-follow-up, as well as group differences
(i.e., self-reported distress and/or elevated scores vs. no
self-reported distress and no elevated scores) were per-
formed. Scores were compared using t-tests or chi-
squared tests, as appropriate, with a significance cut-off
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value of p < 0.05. The relationship between baseline and
follow-up psychological distress was also explored.
To test the first objective, a descriptive analysis of the
investigator-generated item in the final survey, which
assessed self-reported screening of depression and anx-
iety and the outcome of such screening, was performed.
To test the second objective, participants who self-
reported currently experiencing psychosocial distress
and/or scored above the thresholds indicating elevated
distress on the BDI-II or PHQ-2 were described and se-
lected. A descriptive analysis of psychosocial treatment
at baseline and at follow-up was performed. Among
those receiving treatment, description of treatment and
provider type was performed. To test objectives d-f, par-
ticipants who were prescribed pharmacological therapy
were selected. Next, a descriptive analysis of the drug
classification, medication adherence, and the frequency
of medication and/or dosage change from baseline to
follow-up assessment was performed.
To test the final objective, a multiple linear regression
was undertaken to examine whether receipt of any treat-
ment recorded on the follow-up survey (yes/no) was as-
sociated with depressive and anxious symptom severity
at the follow-up visit, in those with elevated symptoms
of psychosocial distress at baseline. The model adjusted
for significant group differences (i.e., self-reported dis-
tress and/or elevated scores vs. no self-reported distress
and no elevated scores) in socio-demographic, clinical
and psychosocial characteristics, as well as sociodemo-
graphic and clinical variables shown to be associated
with follow-up depressive and anxious symptom severity
at the bivariate level.
Results
Respondent characteristics
Of the 191 participants, 128 (67.0%) completed baseline
and 6-month follow-up surveys analyzed in this secondary
analysis. As shown in Fig. 1, 63 participants were lost to
follow-up. Table 1 displays the baseline socio-demographic,
clinical and psychosocial characteristics of the retained and
non-retained sample. As shown, there were no significant
differences in socio-demographic or clinical characteristics
between groups. However, participants lost-to-follow-up
(51.7%) were more likely to have a self-reported history of
depression or anxiety than retained participants (32.8%).
No other psychosocial differences were found between
retained participants and those lost to follow-up.
Burden of psychosocial distress
As also shown in Table 1, there were 56 (43.8%) retained
participants who were experiencing elevated symptoms
of psychosocial distress at baseline. Those with elevated
distress symptoms were significantly more likely to have
a self-reported history of depression or anxiety, as well
as self-reported history of treatment for depression or
anxiety than those without distress. Participants with el-
evated symptoms were also significantly younger, had a
higher body mass index, and were more likely to have
undergone percutaneous coronary intervention (PCI)
than participants without elevated symptoms.
At follow-up, 14 (10.8%) had elevated scores on the
HADS-D and 37 (28.7%) on the HADS-A. Based on the
PHQ-2, 44 (35.8%) participants were considered to be
experiencing elevated symptoms of psychosocial distress
(no significant difference between the number of women
with elevated symptoms at baseline and follow-up;
McNemar test p > 0.05). A significant reduction between
baseline and follow-up PHQ-2 symptom scores was
found for women with elevated symptoms at baseline
(mean difference =−0.62; paired t = 2.96, p < 0.01). Table 2
displays follow-up psychosocial indicators among
women with elevated symptoms of psychosocial distress
Fig. 1 Flow Diagram
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and those without at baseline. At follow-up, those with
elevated symptoms at baseline still had significantly
higher symptom scores on psychometrically-validated
scales than participants without elevated symptoms, but
their mean scores fell below the established cut-offs.
Those with elevated symptoms at baseline were also
more likely to report psychosocial distress screening at
follow-up than those without elevated symptoms. No
differences in exercise behavior, medication adherence
or CR use were observed.
Screening
Forty-two (34.4%) participants self-reported on the
follow-up survey that they recalled being asked about
their mood and/or anxiety by any healthcare provider
during the course of their medical care. Forty-eight
(40.3%) participants reported they recalled being
formally screened for psychosocial distress, of which 33
(27.7%) reported completing a paper-and-pencil screen,
6 (5.0%) a structured interview, and 9 (7.6%) reported
completing both. At baseline, 18 (15.3%) participants
Table 1 Participant characteristics at baseline (N = 191)
Characteristics Retained participants Lost-to
follow-up
Total
Self-reported distress
and/or elevated scores
n = 56 (43.8%)
No self- reported distress
and/or elevated scores
n = 72 (56.3%)
Total
N = 128
n = 63 N = 191
Sociodemographic
Age, years (mean ± SD) 63.25 ± 9.05 67.48 ± 10.81 65.63 ± 10.25* 64.72 ± 9.88 65.32 ± 10.11
Marital Status, n (% married) 27 (48.2) 39 (54.2) 66 (51.6) 31 (49.2) 97 (50.8)
Work Status, n (% retired) 26 (46.4) 41 (56.9) 67 (52.3) 29 (46.0) 76 (54.7)
Highest Education, n (% post-secondary) 17 (30.4) 29 (40.3) 46 (35.9) 20 (31.7) 66 (34.6)
Ethnicity, n (% white) 37 (66.1) 49 (68.1) 86 (67.2) 43 (68.3) 129 (67.5)
Annual Family Income, n (% $50000CDN
or greater)
29 (51.8) 46 (63.9) 75 (58.6) 38 (60.3) 113 (59.2)
Children, n (% yes) 43 (79.6) 59 (83.1) 102 (81.6) 53 (85.5) 155 (82.9)
Clinical
Cardiac Indication
PCI (% yes) 26 (50.0) 30 (44.8) 56 (47.9) 22 (36.7) 78 (43.6)
Angina/ACS/CAD (% yes) 22 (43.1) 21 (31.8) 43 (36.8) 28 (46.7) 71 (40.1)
MI (% yes) 19 (36.5) 22 (33.3) 41 (34.7) 17 (28.3) 58 (32.6)
CABG (% yes) 7 (13.5) 22 (32.8) 29 (24.4)* 16 (26.7) 45 (25.1)
Valve (% yes) 9 (17.3) 17 (25.8) 26 (22.0) 9 (15.0) 35 (19.7)
BMI (mean ± SD) 30.17 ± 7.05 27.34 ± 5.52 28.91 ± 6.53* 29.64 ± 7.24 29.15 ± 6.75
Diabetes, n (% yes) 14 (35.0) 9 (19.1) 23 (26.4) 17 (35.4) 40 (29.6)
Hypertension, n (% yes) 32 (71.1) 44 (74.6) 76 (73.1) 39 (73.6) 115 (73.2)
Dyslipidemia, n (%) 36 (92.3) 44 (81.5) 80 (86.0) 41 (82.0) 121 (84.6)
Exercise Behavior (mean ± SD) 21.33 ± 19.74 20.86 ± 14.99 21.07 ± 17.20 16.92 ± 31.35 19.68 ± 22.93
Psychosocial
Self-Reported History of Depression or Anxiety,
n (% yes)
25 (45.5) 15 (22.4) 40 (32.8)** 31 (51.7) 71 (39.0)†
Self-reported History of Pharmacological Treatment
for depression or anxiety, n (% yes)
15 (27.3) 12 (17.6) 27 (22.0)*** 13 (22.0) 40 (22.0)
Self-reported History of Psychotherapy for
depression or anxiety, n (% yes)
17 (31.5) 14 (20.9) 31 (25.6)* 21 (35.6) 52 (28.9)
BDI-II (mean ± SD) 16.94 ± 11.30 5.08 ± 3.59 9.89 ± 9.64*** 11.31 ± 8.42 10.35 ± 9.26
PHQ-2 (mean ± SD) 1.90 ± 1.89 0.33 ± 0.59 1.03 ± 1.54*** 1.43 ± 2.14 1.15 ± 1.75
PCI percutaneous coronary intervention, ACS acute coronary syndrome, CAD coronary artery disease, CDN Canadian dollars, MI myocardial infarction, CABG
coronary artery bypass graft, BMI body mass index, BDI beck depression inventory, PHQ patient health questionnaire
*Denotes difference between participants with elevated vs. no elevated symptoms (*p <0 .05; **p <0 .01; ***p < 0.001)
†Denotes difference between participants who were retained vs. not retained at 6 month follow-up (†p < 0.05; † p < 0.01; †††p <0.001)
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scored above the American Heart Association’s screen-
ing threshold on the PHQ-2, at which point follow-up
administration of the PHQ-9 is recommended7. Finally,
the number of participants who reported being asked
about their mood and undergoing formal screening did
not significantly differ in those who ultimately enrolled
in CR following referral versus those who did not (p =
0.46 and p = 0.11, respectively).
Of those who reported being formally screened, 10
(21.3%) had their results discussed with them. The out-
comes of formal screening were (participants were asked to
check all that apply): appropriately nothing (n = 16, 42.1%),
pharmacology prescription (n = 6; 15.8%), referral to a men-
tal health professional (n = 5; 10.4%), follow-up by a health-
care provider (n = 6; 15.8%), current problems with mood
or anxiety and nothing (n = 4; 10.5%), referral for other
mental health treatment (n = 1; 2.7%), other (n = 5; 12.8%),
and unknown by participant (n = 2; 5.1%).
With regard to the relationship between screening and
psychosocial distress, there were no significant differences
in depressive symptom severity at baseline (BDI-II: 12.27
± 12.25 vs. 8.33 ± 7.57; p = 0.09) or at follow-up (HADS-D:
3.83 ± 4.00 vs. 3.13 ± 3.09; p = 0.28) (HADS-A: 6.25 ± 4.30
vs. 4.89 ± 4.41; p = 0.10), between participants who
recalled being screened and those who did not. With
regard to the PHQ-2, there was no significant difference
in scores at baseline (1.35 ± 1.62 vs. 0.85 ± 1.50; p = 0.10)
between participants who recalled screening and those
who did not, but there was a significant difference found
at follow-up (1.21 ± 1.80 vs. 0.57 ± 1.00; p = 0.03) with
those who recalled screening scoring higher.
Treatment of distressed women
Ninety-two (48.2%) women were considered to be experi-
encing elevated psychosocial distress at the initial assess-
ment (of which 56 participants were retained at follow-up).
Of these 56, 25 (44.6%) reported receiving some form of
treatment at baseline. Of these, 20 (80.0%) reported still re-
ceiving treatment at follow-up, and 5 (20.0%) reported they
were not. Again, of those 56 distressed women at baseline,
26 (48.1%) were receiving some form of treatment at
follow-up (i.e., 20 participants + 6 new). The number of par-
ticipants receiving treatment did not significantly differ be-
tween baseline and follow-up assessment (McNemar test
p > 0.05). Table 3 displays the types of treatment, as well as
who was providing or supervising it, at both assessment
points. As shown, most participants received medication,
followed by one-fourth receiving a combination of medica-
tion and counselling, with the least proportion of treated
participants receiving counselling alone.
Of those receiving treatment, 21 (84.0%) were taking psy-
choactive medications at baseline and 24 (92.3%) were tak-
ing them at follow-up. Their overall mean medication
adherence score was 3.60 ± 0.68 at baseline and 3.42 ± 0.97
at follow-up, with no participants considered “non-adherent
at baseline and 2 (8.3%) considered “non-adherent” at
follow-up. Table 3 also displays the class of psychoactive
medication taken at both time points. The same medication
was reported at both assessment points for 11 (84.6%)
participants, for which 2 (15.4%) participants reported a
change in dosage over time (one increased and one
decreased). Two (15.4%) participants reported a change in
psychoactive medication from baseline to follow-up: one
from selective serotonin reuptake inhibitor to a serotonin
norepinephrine reuptake inhibitor, and one switched
medications within the atypical class.
Treatment effect
Participants who were receiving any form of treatment
at baseline had significantly higher anxious (10.12 ± 4.61
vs. 5.89 ± 3.68) symptom HADS scores at follow-up than
those who were not receiving treatment (p < 0.001).
Table 2 Follow-up psychosocial and other indicators among women by psychosocial distress status at baseline (N = 128)
Variable Self-reported distress
and/or elevated scores
n = 56 (43.8%)
No self-reported distress
and/or elevated scores
n = 72 (56.3%)
Total
Psychosocial Symptomsa
Depressive Symptoms (PHQ-2) 1.37 ± 1.67 0.42 ± 0.95 0.83 ± 1.39***
Depressive Symptoms (HADS-D) 5.16 ± 4.08 2.14 ± 2.11 3.45. ± 3.45***
Anxious Symptoms (HADS-A) 7.96 ± 4.55 3.57 ± 2.99 5.47 ± 4.32***
Psychosocial Distress Screening (% yes) 25 (47.2) 17 (24.6) 42 (34.4)**
Exercise Behaviour (Godin)a 29.19 ± 27.51 34.99 ± 33.14 32.43 ± 30.79
Medication Adherence (MMAS)a 3.50 ± 0.81 3.64 ± 0.68 3.58 ± 0.74
Enrolled in CR (% yes) 48 (85.7) 65 (91.5) 113 (89.0)
Completed CR (% yes) 34 (77.3) 46 (88.5) 80 (83.3)
PHQ patient health questionnaire, HAD-A and HAD-D hospital anxiety and depression scale, MMAS Morisky’s medication adherence scale
*p < 0.05; **p <0 .01; ***p < 0.001 for t-test or chi-square comparing indicators by psychosocial distress status, as appropriate
amean and standard deviation
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There were no differences in depressive (6.28 ± 4.38 vs.
4.23 ± 3.61; p > 0.05) symptom HADS scores. Partici-
pants who were receiving any form of treatment at
follow-up had significantly higher depressive (6.46 ± 4.37
vs. 3.93 ± 3.52) and anxious (10.23 ± 4.63 vs. 5.75 ± 3.34)
symptom HADS scores at follow-up than those who
were not receiving treatment (p < 0.05 and p < 0.001,
respectively).
An analysis of treatment effects on change in depressive
symptoms in distressed patients was undertaken. Among
participants who were distressed at baseline, participants
who received any form of treatment experienced a non-
significant reduction in symptoms (2.37 ± 2.03 at pre-test
and 2.00 ± 1.93 at post-test, p = 0.27) on the PHQ-2,
whereas distressed participants not receiving treatment
experienced a significant symptom reduction (1.48 ± 1.73
at pre-test and 0.60 ± 1.08 at post-test, p < 0.01). Table 4
displays analysis of correlates of symptoms of depression
and anxiety at follow-up. Unadjusted analyses showed that
greater baseline psychosocial distress symptom scores
were significantly associated with greater symptom scores
of depression and anxiety at follow-up. Moreover, older
age was found to be significantly related to lower follow-
up anxious symptom severity.
Two multiple linear regressions were performed to as-
certain whether receipt of any treatment (independent
variable) was related to psychosocial distress scores at
follow-up (i.e., HADS-D and HADS-A; dependent vari-
ables). The model was adjusted for baseline symptom
scores and age (i.e., significant differences identified in
Table 4), as well as cardiac indication and self-reported
history of psychosocial distress (i.e., primary significant
differences identified in Table 1). PHQ-2 scores were not
included due to their correlation with BDI-II scores. The
results are shown in Table 5. The models overall were sig-
nificant (F = 3.45, p < 0.05; F = 3.10, p = <0.05, respectively),
Table 3 Treatment of patients who were considered distressed
at baseline, by assessment point
Baseline
(n = 25; 44.6%
treated)
Follow-up
(n = 26; 48.1%
treated)
Treatment Type
Medication 15 (60.0) 17 (65.4)
Combination 6 (24.0) 7 (26.9)
Counseling 4 (16.0) 2 (7.7)
Type of Providera
Family Doctor 16 (69.6) 19 (82.6)
Psychiatrist or
Psychologist
7 (30.4) 7 (30.4)
Nurse 1 (4.3) 2 (9.1)
Cardiologist 1 (4.3) 2 (8.7)
Other 2 (8.7) 4 (17.4)
Class of Psychoactive Medicationab
SSRI 4 (25.0) 5 (23.8)
Atypical antidepressantc 7 (43.8) 6 (28.6)
Benzodiazepines 4 (25.0) 8 (38.1)
SNRI 5 (31.3) 5 (23.8)
TCA 2 (12.5) 2 (10.0)
aNote that some women reported receiving treatment from more than one
type of provider and taking more than one psychoactive medication
SSRIs selective serotonin reuptake inhibitors, SNRIs serotonin norepinephrine
reuptake inhibitors, TCA tricyclic antidepressants
bIncludes those treated with medication (n = 21 and n = 24, respectively)
cfor example: Mirtazapine, Bupropion and Trazodone
Table 4 Sociodemographic and clinical correlates of depressive
and anxious symptom severity at follow-up (N = 56)
Depressiona
t / r
Anxietya
t / r
Sociodemographic
Age −.174 −.277*
Marital Status (married) .137 .646
Work Status (retired) .049 −.832
Highest Education (post-secondary) −.150 .648
Ethnicity (white) .560 −.166
Annual Family Income ($50000CDN or
greater)
−.553 −1.626
Children (yes) −.123 −1.163
Clinical
Cardiac Indication
PCI (yes) −1.249 −.885
Angina/ACS/CAD (yes) −.998 −1.412
MI (yes) −.618 −.555
CABG (yes) .575 .644
Valve (yes) −.741 −.517
BMI .101 .023
Exercise Behavior (Godin)a .054 −.143
Diabetes (yes) 1.502 .006
Hypertension (yes) .326 −.800
Dyslipidemia (yes) −.213 −1.971
CR Enrollment (yes)a −.064 −.694
CR Completion (yes)a −.994 −.747
Psychosocial
Treatment (yes)a 2.356* 4.099***
BDI-II .566*** .465**
PHQ-2 .573*** .484***
PHQ-2a .747*** .735***
PCI percutaneous coronary intervention, ACS acute coronary syndrome, CAD
coronary artery disease, CDN Canadian dollars, MI myocardial infarction, CABG
coronary artery bypass graft, BMI body mass index, BDI beck depression
inventory, PHQ patient health questionnaire
*p < 0.05; **p <0 .01; ***p < 0.001 for t-test and Pearson’s correlation (r),
as applicable
aAssessed at follow-up. All other variables assessed at baseline
Hurley et al. BMC Women's Health  (2017) 17:11 Page 7 of 11
and were amply powered (0.94 and 0.90, respectively). The
effect of treatment on depressive symptoms at follow-up
did not sustain adjustment, suggesting that pharmacologic
or counseling treatments did not affect depressive symp-
tom scores. The effect of treatment on anxious symptom
severity did sustain adjustment, suggesting that pharmaco-
logic or counseling treatments were related to greater anx-
ious symptoms. As shown, depressive symptom scores at
follow-up were significantly related to psychosocial distress
symptom scores at baseline, but anxious symptom scores
were not (trend). No other variables in the model were
found to be significantly related.
Discussion
These findings reiterate the great burden of psychosocial
distress among women with CVD [35], with approximately
half of women displaying elevated symptoms. Despite
screening recommendations, less than half of women car-
diac patients recalled being formally screened. Moreover,
less than half of women with elevated symptoms were re-
ceiving treatment. Regardless, receiving treatment had no
significant impact on depressive symptoms and was related
to greater, not lesser anxious symptom severity. The direc-
tion of effect for this association is likely that women ex-
periencing anxiety are more actively soliciting treatment
(i.e., reverse causality). While a structured clinical interview
is needed to confirm a psychological disorder and whether
treatment is warranted, these findings certainly corroborate
previous reports of insufficient [36, 37] and even inappro-
priate [38, 39] (i.e., Tricyclic Antidepressants) treatment of
these important co-morbidities.
Implications related to screening
Despite recommendations, depression is not routinely
identified in cardiac patients [40], a finding that was reit-
erated in the current study. Shanmugasegaram et al.
[35]. found that only 28.7% of coronary artery disease
patients recalled being screened for depression following
a cardiac hospitalization, and 32.5% of patients enrolled
in CR recalled being screened. The rates in our study
were somewhat higher. First, this could be explained by
recent uptake of depression screening recommendations.
Second, patients in this study would have had the oppor-
tunity to be screened in-hospital at the time of cardiac
event, but also potentially at CR given there are screen-
ing recommendations for both settings. Third, because
the sample was comprised solely of women who are
known to suffer from greater rates of depression, health-
care providers may have screened more often. While the
rates were closer to 50%, and patients may have forgot-
ten they were screened, clearly the recommendations for
screening have still not been consistently implemented.
The reasons for low depression screening rates likely in-
clude the critique of the American Heart Association rec-
ommendations by Thombs et al. [41]. While the results of
this secondary analysis cannot be considered conclusive
evidence, findings would suggest that screening recall was
not related to lower depressive symptoms among female
cardiac patients 6 months later. Thus, these findings sug-
gest research is needed on actual screening in the CR set-
ting and the effects on downstream symptoms and health
outcomes [42].
There was certainly a trend towards more severe depres-
sive symptoms at baseline in women who recalled being
screened, as well as more severe symptoms of depression
and anxiety at follow-up, and this may be indicative that
providers are selectively screening patients they suspect
may be experiencing depression (or it may reflect that
women with greater distress are more likely to recall being
screened). It has been suggested that case-finding for de-
pression might be a more cost and resource-effective strat-
egy than universal screening [41].
The CR context may present an important opportunity
to screen and address comorbid depression and psycho-
social distress [19]. There are CR-specific screening
recommendations in Canada where the study was con-
ducted [10], and in the United States [9]. In both coun-
tries depression screening is considered a quality
indicator, although anxiety screening is not [43, 44].
Thus, it was surprising that patients who enrolled in CR
following referral did not recall greater rates of depres-
sion screening than patients who did not enroll. It is
Table 5 Adjusted multiple linear regression model examining the association of treatment with depressive and anxious symptom
severity at follow-up (N = 56)
Depressive symptoms Anxiety symptoms
Variable β SE p 95% CI β SE p 95% CI
Lower bound Upper bound Lower bound Upper bound
Treatment −.636 1.491 .673 −3.677 2.404 −3.408 1.584 .039 −6.638 −.178
Psychosocial Distress at Baseline (BDI-II) .208 .064 .003 .077 .339 .137 .060 .053 −.002 .276
History of Psychosocial Distress −.571 1.497 .705 −3.625 2.482 −.978 1.590 .543 −2.266 4.221
Age −.076 .077 .331 −.234 .081 −.111 .082 .185 −.279 .056
CABG −.300 1.849 .872 −4.070 3.470 .168 1.964 .932 −3.837 4.173
CABG coronary artery bypass graft, BDI beck depression inventory, CI confidence interval, SE standard error
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hoped results from this study will initiate discussion on
the role of screening in the CR setting.
Implications for treatment
A number of studies have examined the effect of in-
hospital depression screening on patient outcomes [45–47].
Results of these studies suggest that when screening is
combined with “collaborative care”, patients can achieve
significant reductions in depressive symptoms [45–47]. Col-
laborative care involves several healthcare providers
working together to deliver care [48], including frequent
check-ins, medication adjustments, promotion of treatment
adherence and disease-related education [45, 46]. Our re-
sults suggest that few women recall being screened, and less
than half of the women who were distressed received any
form of treatment, so it is most unlikely that the above ben-
efits could be achieved. It is postulated that there is insuffi-
cient capacity to ensure effective treatment is available for
all patients who screen positive, given the chronic under-
funding of CR services, which may serve as a deterrent to
screening. Perhaps it is time to increase the availability of
psychologists and psychiatrists in CR to ensure that proven
models of collaborative care are instituted.
Our findings are not consistent with many of the
major CVD and psychosocial distress trials, which
showed that psychoactive drugs, psychotherapy, or a
combination of the two, improve psychological out-
comes [14–17]. Our data are pragmatic and observa-
tional, and suggest that distressed women are: (a) not
getting sufficient therapy, (b) may need to change or
introduce additional therapeutic modalities to achieve
symptom control and remission, or (c) not adhering to
the medication for a sufficient duration to achieve re-
mission, although it is important to note that our results
are based upon self-report data in only a small sample of
women. In the case of pharmacological treatment, which
was the primary form of treatment in the current sam-
ple, it is known that individuals being treated with psy-
choactive drugs are not put on an full therapeutic dose
right away to reduce the chance of side effects, such that
optimal treatment efficacy may not be reached without
up-titration [12]. Patients should be followed-up with by
their physician to observe how they are tolerating the
medication, whether they are experiencing side effects,
and to up-titrate the dose if needed (to balance efficacy
and safety) [12]. Our results suggest patients may not be
receiving adequate follow-up, as only 1/3 of those
treated pharmacologically reported any change in medi-
cation (i.e., type or dose change; although we do not
have data on the frequency of follow-up visits to the
treating healthcare professional). It has been reported
that only 20–30% of patients undergoing depression
treatment receive adequate care and follow-up in the
primary care setting [7].
Caution is warranted when interpreting these findings,
particularly due to measurement issues. First, the protocol
did not include a structured clinical interview to formally
diagnose depression or anxiety, so the number of partici-
pants with a major depressive disorder or anxiety disorder
is unknown, as is the appropriateness of the rates of treat-
ment. Self-report of symptoms of depression and anxiety is
subject to under-reporting bias. Moreover, it has been
found that brief depression screening tools can have un-
acceptably low specificity rates. The PHQ-2 screening tool,
which was one of measures used in this study, may have
only 52% specificity in cardiac samples [49]. This suggests
that approximately half of the patients who scored above
the cutoff on this tool may not warrant depression treat-
ment. Second, while the PHQ-2 was administered in both
assessments, different scales were used to measure symp-
toms of psychosocial distress pre and post-CR (i.e., BDI-II
at pre-test and HADS at post-test) due to a change made
for the larger trial. The change was made by the investiga-
tors to add anxiety assessment, while limiting an increase
in survey response burden which would occur by the
addition of another scale. Additionally, rates of distress
screening and identification may be under-reported due to
possible recall bias [50, 51]. Third, screening was only
ascertained through participant report, and patients may
have been unaware or forgotten screening that had oc-
curred months prior leading to under-reporting. Future re-
search is needed where screening is verified in medical
charts. Fourth, the CR programs where participants were
referred in this study routinely administer a paper-and-
pencil depression survey; however we did not verify this in
CR charts. Taken together, the incorporation of longitudinal
data and medical record information in combination with
our prospective self-report data would have enabled more
fulsome testing of some of our objectives.
Fifth, due to the nature of the study design, causality in
the relationship between the variables of interest and symp-
tom control cannot be inferred. Sixth, results are limited by
selection and retention bias. With regard to the former, it is
not known how participants who consented to participate
in the randomized trial from which this sample was drawn
differed from those who did not, however previous research
has suggested that there are some important differences
which may impact the generalizability of these findings
[52]. With regard to the latter, while the only observed dif-
ference between those retained and lost to follow-up was in
the rate of self-reported history of depression or anxiety,
there may be unmeasured factors which introduce a bias in
our retained sample. Seventh, because the associations
assessed herein were not tested on a primary basis, the re-
quired sample size for sufficient power was not determined
a priori. Post-hoc calculations revealed the comparison of
depressive symptom scores at post-test by receipt of treat-
ment was well-powered (.98), however the comparison by
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screening recall was not (.46). Replication is warranted to
test the latter association, in an appropriately-powered
sample. Finally, we did not assess the history of psychosocial
distress in the patients, when they were diagnosed and how
this may have inter-related with their development of CVD.
Conclusion
These findings reiterate the great burden of psychosocial
distress in women cardiac outpatients. Despite guideline
recommendations, screening recall was low and unrelated
to depressive symptom severity 6 months later. Where
treated, most women were often prescribed psychoactive
medication under the supervision of their family physi-
cians. However, symptom reduction in those receiving any
form of treatment was not achieved. More research
investigating the effects of screening and developing cost-
effective mental health interventions for cardiac patients
in the CR setting is needed.
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